Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 3/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305393 | 1.00 | ADORA2A (0.44) | ADORA2ARNASEH1ADORA1KCNH2PNP | |
| SCHEMBL31305567 | 0.93 | ADORA2A (0.42) | ADORA2ARNASEH1ADORA1KCNH2PNP | |
| SCHEMBL2867396 | 0.93 | ADORA2A (0.42) | ADORA2ARNASEH1ADORA1KCNH2PNP | |
| SCHEMBL31305556 | 0.91 | NR1H2 (0.40) | ADORA2AKCNH2KMOAHRLMNA | |
| SCHEMBL2871695 | 0.91 | NR1H2 (0.40) | ADORA2AKCNH2KMOAHRLMNA | |
| SCHEMBL31305503 | 0.90 | ADORA2A (0.44) | ADORA2ARNASEH1ADORA1PNPTYMP | |
| SCHEMBL26109457 | 0.90 | ADORA2A (0.44) | ADORA2ARNASEH1ADORA1PNPTYMP | |
| SCHEMBL2871545 | 0.90 | ADORA2A (0.41) | ADORA2ARNASEH1ADORA1KCNH2PNP | |
| SCHEMBL3362112 | 0.89 | ADORA2A (0.42) | ADORA2ARNASEH1ADORA1KCNH2CXCR2 | |
| SCHEMBL31305428 | 0.89 | ADORA2A (0.42) | ADORA2ARNASEH1ADORA1KCNH2CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-4506488-A1 | SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY | Shikoku Chemicals Corporation (JP) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023190263-A1 | SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY | 四国化成工業株式会社 | 2023-10-05 | — | — | WO | disclosed |
| CN-102119240-B | Surface treating agent for copper or copper alloy and use thereof | SHIKOKU CHEM | 2014-07-30 | — | — | CN | disclosed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
| US-6673941-B2 | Disubstituted imidazoles useful in the treatment of bacterial infections | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-01-06 | — | — | US | disclosed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-6559172-B1 | Treatment of bacterial infections, particularly through the inhibition of FAB I. and antiobiotics | SMITHKLINE BEECHAM CORPORATION | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | ADORA2A 3924/4885RNASEH1 383/4885ADORA1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.